North America Human Insulin Drugs Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

North America Human Insulin Drugs Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The North America Human Insulin Drug Market is expected to register a CAGR greater than 4% by the forecast period (2022-2027).

In North America diabetes incidence for type 2 diabetes as well as other diabetes, forms were numerically higher in individuals with Covid-19. Insulin resistance and impaired insulin secretion have been described in individuals without diabetes history who recovered from SARS-CoV-2 infections. It has been suggested that diagnosis and treatment of post-Covid syndrome require integrated rather than disease-specific approaches.

North America dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs in the region. United States is expected to grow tremendously during the forecast period, owing to factors, such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsLantus Holds The Highest Market Share in 2021

Lantus was approved by the US Food and Drug Administration (FDA) in April 2000. Lantus is a man-made form of hormone (insulin) that is produced in the body. Insulin is a hormone that works by lowering levels of glucose (sugar) in the blood. Insulin glargine is a long-acting insulin that starts to work several hours after injection and keeps working evenly for 24 hours. Lantus is for use in adults with type 1 or types 2 diabetes, and in children at least 6 years old with type -1 Diabetes. For type 1 diabetes, Lantus is used together with short-acting insulin given before meals. Lantus and Januvia, two treatments for diabetes are some of the highest-selling drugs of all time and represent some of the greatest breakthroughs in diabetes control.

United States was the largest market for Lantus in 2021, accounting for more than 58% of the market revenues. However, the biosimilars for Lantus may not present it with competitive challenges currently. The loss of exclusivity for Lantus may not result in the near-term disruption of the market for it. However, there will be additional pricing pressure and some loss of market share that would continue and may increase over time.

United States Holds Highest Market Share in 2021

Among the North American countries, United States dominates around 94% of the total North America Human Insulin Drugs Market. This is mainly due to the high diabetes prevalence in the country. United States records the highest healthcare expenditure globally, and it also has a higher adoption of advanced therapeutics. United States accounts for the highest sales of long-acting insulin, Lantus, across the North America Region. Most diabetic drug manufacturing companies consider the country as a critical market for improving overall global sales. Lantus is the most administered basal insulin across the world, accounting for a dominant share in United States market.

United States accounts for the highest sales of Humalog across the world, with over 56% of the market share. The majority of the diabetes drug manufacturing companies consider the country a critical market for improving overall global sales. In United States, Humalog is available in different varieties under names like Humalog Mix 75/25, Humalog U-100, Humalog U-200, and Humalog Mix 50/50 for the treatment of diabetes.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.

Competitive Landscape

The North American human insulin market is highly fragmented, with three major manufacturers having a large market share. In United States, there are no other players except Novo Nordisk, Sanofi, and Eli Lilly. While in the remaining countries, the manufacturers confine to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies to strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine).

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.